BioMarin Pharmaceutical Shares Outstanding 2006-2019 | BMRN

BioMarin Pharmaceutical shares outstanding history from 2006 to 2019. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • BioMarin Pharmaceutical shares outstanding for the quarter ending March 31, 2019 were 0.178B, a 1.2% increase year-over-year.
  • BioMarin Pharmaceutical 2018 shares outstanding were 0.177B, a 1.63% increase from 2017.
  • BioMarin Pharmaceutical 2017 shares outstanding were 0.174B, a 4.94% increase from 2016.
  • BioMarin Pharmaceutical 2016 shares outstanding were 0.166B, a 3.87% increase from 2015.
BioMarin Pharmaceutical Annual Shares Outstanding
(Millions of Shares)
2018 177
2017 174
2016 166
2015 160
2014 146
2013 138
2012 120
2011 112
2010 126
2009 100
2008 104
2007 96
2006 85
2005 69
BioMarin Pharmaceutical Quarterly Shares Outstanding
(Millions of Shares)
Q1 2019 178
Q4 2018 177
Q3 2018 177
Q2 2018 177
Q1 2018 176
Q4 2017 174
Q3 2017 175
Q2 2017 174
Q1 2017 173
Q4 2016 166
Q3 2016 168
Q2 2016 163
Q1 2016 162
Q4 2015 160
Q3 2015 161
Q2 2015 160
Q1 2015 158
Q4 2014 146
Q3 2014 159
Q2 2014 146
Q1 2014 144
Q4 2013 138
Q3 2013 141
Q2 2013 140
Q1 2013 128
Q4 2012 120
Q3 2012 123
Q2 2012 118
Q1 2012 115
Q4 2011 112
Q3 2011 112
Q2 2011 111
Q1 2011 111
Q4 2010 126
Q3 2010 131
Q2 2010 102
Q1 2010 104
Q4 2009 100
Q3 2009 102
Q2 2009 101
Q1 2009 100
Q4 2008 104
Q3 2008 103
Q2 2008 104
Q1 2008 104
Q4 2007 96
Q3 2007 96
Q2 2007 96
Q1 2007 95
Q4 2006 85
Q3 2006 86
Q2 2006 85
Q1 2006 75
Q4 2005 69
Q3 2005 72
Q2 2005 65
Q1 2005 65
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $14.607B $1.491B
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $108.806B 12.30
Gilead Sciences (GILD) United States $82.919B 10.07
Celgene (CELG) United States $63.614B 10.78
Biogen (BIIB) United States $44.842B 8.51
Vertex Pharmaceuticals (VRTX) United States $44.598B 53.91
Illumina (ILMN) United States $43.100B 49.95
CSL (CSLLY) Australia $35.794B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.576B 15.31
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.088B 15.33
Incyte (INCY) United States $17.271B 70.04
Exact Sciences (EXAS) United States $14.835B 0.00
SINO PHARMACEUT (SBMFF) China $14.154B 0.00
Seattle Genetics (SGEN) United States $12.140B 0.00
Sarepta Therapeutics (SRPT) United States $11.068B 0.00
Genmab (GNMSF) Denmark $11.046B 56.15
Array BioPharma (ARRY) United States $10.373B 0.00
Galapagos (GLPG) Belgium $9.396B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $8.917B 29.29
Guardant Health (GH) United States $8.158B 0.00
Alnylam Pharmaceuticals (ALNY) United States $8.030B 0.00
Bio-Techne Corp (TECH) United States $7.933B 54.13
Bluebird Bio (BLUE) United States $7.614B 0.00
Exelixis (EXEL) United States $6.419B 16.36
Amarin (AMRN) Ireland $5.979B 0.00
BeiGene (BGNE) Cayman Islands $5.801B 0.00
Ascendis Pharma (ASND) Denmark $4.841B 0.00
Blueprint Medicines (BPMC) United States $4.775B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.762B 0.00
Moderna (MRNA) United States $4.642B 0.00
Horizon Pharma Public (HZNP) Ireland $4.456B 11.48
Repligen (RGEN) United States $4.099B 102.12
Mirati Therapeutics (MRTX) United States $3.821B 0.00
Spark Therapeutics (ONCE) United States $3.720B 0.00
ACADIA Pharmaceuticals (ACAD) United States $3.705B 0.00
China Biologic Products (CBPO) China $3.661B 23.25
Alkermes (ALKS) Ireland $3.651B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.569B 0.00
MorphoSys AG (MOR) Germany $3.528B 0.00
Arena Pharmaceuticals (ARNA) United States $3.064B 6.23
Amicus Therapeutics (FOLD) United States $2.934B 0.00
Immunomedics (IMMU) United States $2.860B 0.00
UniQure (QURE) Netherlands $2.736B 0.00
Medicines (MDCO) United States $2.670B 0.00
Reata Pharmaceuticals (RETA) United States $2.620B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.595B 0.00
MyoKardia (MYOK) United States $2.466B 0.00
Halozyme Therapeutics (HALO) United States $2.370B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.357B 0.00
NeoGenomics (NEO) United States $2.277B 149.06
Emergent Biosolutions (EBS) United States $2.269B 19.71
Ligand Pharmaceuticals (LGND) United States $2.233B 18.49
Acceleron Pharma (XLRN) United States $2.230B 0.00
Myriad Genetics (MYGN) United States $2.092B 20.81
Genomic Health (GHDX) United States $2.075B 44.07
Zai Lab (ZLAB) China $2.068B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.044B 0.00
Akcea Therapeutics (AKCA) United States $2.041B 0.00
Denali Therapeutics (DNLI) United States $1.988B 0.00
REGENXBIO (RGNX) United States $1.800B 0.00
Insmed (INSM) United States $1.720B 0.00
Cambrex (CBM) United States $1.514B 19.15
AnaptysBio (ANAB) United States $1.474B 0.00
RA PHARMCTL INC (RARX) United States $1.418B 0.00
Fate Therapeutics (FATE) United States $1.393B 0.00
Innoviva (INVA) United States $1.361B 3.76
Sangamo Therapeutics (SGMO) United States $1.338B 0.00
Alector (ALEC) United States $1.298B 0.00
Athenex (ATNX) United States $1.278B 0.00
Coherus BioSciences (CHRS) United States $1.226B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.185B 0.00
Editas Medicine (EDIT) United States $1.174B 0.00
Epizyme (EPZM) United States $1.156B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.032B 0.00
Cara Therapeutics (CARA) United States $1.030B 0.00
Codexis (CDXS) United States $1.011B 0.00
Twist Bioscience (TWST) United States $0.982B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.25
Zymeworks (ZYME) Canada $0.952B 0.00
Momenta Pharmaceuticals (MNTA) United States $0.947B 0.00
Principia Biopharma (PRNB) United States $0.921B 0.00
Adverum Biotechnologies (ADVM) United States $0.891B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.884B 0.00
Retrophin (RTRX) United States $0.879B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Vericel (VCEL) United States $0.822B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.820B 0.00
WAVE Life Sciences (WVE) Singapore $0.794B 0.00
Arvinas (ARVN) United States $0.789B 0.00
Intellia Therapeutics (NTLA) United States $0.782B 0.00
Precision BioSciences (DTIL) United States $0.701B 0.00
Zealand Pharma (ZEAL) Denmark $0.692B 8.08
Vanda Pharmaceuticals (VNDA) United States $0.688B 32.47
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Intra-Cellular Therapies (ITCI) United States $0.652B 0.00
Cytokineticsorporated (CYTK) United States $0.643B 0.00
Cellectis S.A (CLLS) France $0.634B 0.00
Heska (HSKA) United States $0.622B 63.66
Autolus Therapeutics (AUTL) United Kingdom $0.612B 0.00
DBV Technologies S.A (DBVT) France $0.600B 0.00
Stemline Therapeutics (STML) United States $0.588B 0.00
Clovis Oncology (CLVS) United States $0.580B 0.00
Anika Therapeutics (ANIK) United States $0.577B 19.72
Lexicon Pharmaceuticals (LXRX) United States $0.561B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.560B 0.00
Revance Therapeutics (RVNC) United States $0.554B 0.00
CytomX Therapeutics (CTMX) United States $0.527B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
MiMedx (MDXG) United States $0.503B 0.00
Mesoblast (MESO) Australia $0.494B 0.00
PHARMA MAR SA (PHMMF) Spain $0.452B 0.00
UROGEN PHARMA (URGN) United States $0.438B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.437B 0.00
Puma Biotechnology (PBYI) United States $0.394B 0.00
Prothena (PRTA) Ireland $0.393B 0.00
AC Immune SA (ACIU) Switzerland $0.378B 24.35
PDL BioPharma (PDLI) United States $0.376B 8.97
Biofrontera AG (BFRA) Germany $0.373B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Arcus Biosciences (RCUS) United States $0.364B 0.00
Gritstone Oncology (GRTS) United States $0.361B 0.00
Starpharma Holdings (SPHRY) Australia $0.360B 0.00
Bellus Health (BLUSF) Canada $0.358B 0.00
Scholar Rock Holding (SRRK) United States $0.345B 0.00
Avid Bioservices (CDMO) United States $0.343B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.342B 0.00
Merus (MRUS) Netherlands $0.341B 0.00
BioDelivery Sciences (BDSI) United States $0.341B 0.00
Albireo Pharma (ALBO) United States $0.340B 0.00
Acorda Therapeutics (ACOR) United States $0.332B 5.85
Agenus (AGEN) United States $0.330B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.330B 0.00
Prometic Life Sciences (PFSCD) Canada $0.322B 0.00
Kadmon Holdings (KDMN) United States $0.321B 0.00
Theratechnologies (THERF) Canada $0.320B 0.00
Sorrento Therapeutics (SRNE) United States $0.319B 0.00
Syros Pharmaceuticals (SYRS) United States $0.314B 0.00
Protagonist Therapeutics (PTGX) United States $0.307B 0.00
Senesco Technologies (ELOX) United States $0.297B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.295B 0.00
Cellular Biomedicine (CBMG) United States $0.277B 0.00
Inovio Pharmaceuticals (INO) United States $0.274B 0.00
Kindred Biosciences (KIN) United States $0.264B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.258B 0.00
Sutro Biopharma (STRO) United States $0.256B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.246B 0.00
PHASEBIO PHARMA (PHAS) United States $0.246B 0.00
ChromaDex (CDXC) United States $0.245B 0.00
Kamada (KMDA) Israel $0.239B 9.28
Dynavax Technologies (DVAX) United States $0.238B 0.00
Geron (GERN) United States $0.229B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.225B 0.00
ADMA Biologics Inc (ADMA) United States $0.224B 0.00
Athersys (ATHX) United States $0.213B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.202B 0.00
Five Prime Therapeutics (FPRX) United States $0.202B 0.00
MannKind (MNKD) United States $0.201B 0.00
Mersana Therapeutics (MRSN) United States $0.200B 0.00
Cerecor (CERC) United States $0.197B 0.00
Affimed (AFMD) Germany $0.193B 0.00
OSMOTICA PHARM (OSMT) United States $0.184B 0.00
POXEL SA FRANCE (PXXLF) $0.184B 0.00
Abeona Therapeutics (ABEO) United States $0.184B 0.00
Synlogic (SYBX) United States $0.179B 0.00
Enzo Biochem (ENZ) United States $0.174B 0.00
Spero Therapeutics (SPRO) United States $0.174B 0.00
Compugen (CGEN) Israel $0.172B 0.00
Arsanis (XFOR) United States $0.168B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
XOMA (XOMA) United States $0.165B 0.00
Nicox SA (NICXF) France $0.161B 0.00
Cue Biopharma (CUE) United States $0.157B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.156B 0.00
Strongbridge Biopharma (SBBP) United States $0.150B 8.66
Liquidia Technologies (LQDA) United States $0.144B 0.00
Celyad SA (CYAD) Belgium $0.142B 0.00
Alcobra (ARCT) United States $0.141B 0.00
OvaScience (MLND) United States $0.141B 0.00
Adocia (ADOCY) France $0.140B 0.00
Windtree Therapeutics (WINT) United States $0.138B 0.00
Dyadic (DYAI) United States $0.136B 0.00
TOCAGEN INC (TOCA) United States $0.135B 0.00
Northwest Biotherapeutics (NWBO) United States $0.130B 0.00
Seres Therapeutics (MCRB) United States $0.127B 0.00
Aptinyx (APTX) United States $0.125B 0.00
NantKwest (NK) United States $0.121B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.114B 0.00
Aduro Biotech (ADRO) United States $0.114B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.110B 0.00
Novavax (NVAX) United States $0.108B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.108B 0.00
Verastem (VSTM) United States $0.106B 0.00
Checkpoint Therapeutics (CKPT) United States $0.104B 0.00
Menlo Therapeutics (MNLO) United States $0.103B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.099B 0.00
Arbutus Biopharma (ABUS) Canada $0.098B 0.00
SESEN BIO, INC (SESN) United States $0.098B 0.00
Trevena (TRVN) United States $0.094B 0.00
Fortress Biotech (FBIO) United States $0.089B 0.00
Pluristem Therapeutics (PSTI) Israel $0.088B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.087B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.084B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.082B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.080B 0.00
Unum Therapeutics (UMRX) United States $0.079B 0.00
VBI Vaccines (VBIV) United States $0.079B 0.00
AquaBounty Technologies (AQB) United States $0.078B 0.00
Curis (CRIS) United States $0.076B 0.00
Selecta Biosciences (SELB) United States $0.076B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.071B 0.00
Idera Pharmaceuticals (IDRA) United States $0.071B 0.00
Applied Genetic Technologies (AGTC) United States $0.071B 38.80
VTv Therapeutics (VTVT) United States $0.070B 0.00
Signal Genetics (MGEN) United States $0.070B 0.00
Orgenesis (ORGS) United States $0.067B 0.00
Oncobiologics (OTLK) United States $0.064B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Antibe Therapeutics (ATBPF) Canada $0.061B 0.00
ARAVIVE, INC (ARAV) United States $0.060B 0.00
NewLink Genetics (NLNK) United States $0.060B 0.00
Organovo Holdings (ONVO) United States $0.060B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.058B 0.00
Prima BioMed (IMMP) Australia $0.057B 0.00
AIT Therapeutics (XAIR) United States $0.057B 0.00